Changes in Cyclooxygenase-2’s Expression, and PGE2 ’s and 6-keto-PGF1α’s Levels in the Presence of the Muscarinic Acethylcholine Receptor Antibody in Primary Sjögren Syndrome by Reina, Silvia Lorena et al.
 
ForschenSci
O p e n  H U B  f o r  S c i e n t i f i c  R e s e a r c h
International Journal of Dentistry and Oral Health
Open Access
Copyright: © 2015 Reina S et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ISSN 2378-7090
Volume: 1.3Research Article
Changes in Cyclooxygenase-2’s 
Expression, and PGE2’s and 6-keto-PGF1α’s 
Levels in the Presence of the Muscarinic 
Acethylcholine Receptor Antibody in 
Primary Sjögren Syndrome
Silvia Reina1,2, Cecilia Pisoni3, Alicia Eimon3, Carolina Carrizo3, Sabrina 
Ganzinelli1,2, Roberto Arana3, and Enri Borda1,2*
1Pharmacology Unit, School of Dentistry, University of Buenos Aires, Buenos Aires, Argentina
2National Research Council of Argentina (CONICET), Buenos Aires, Argentina
3Section of Rheumatology and Immunology, Department of Internal Medicine, CEMIC, Buenos Aires, 
Argentina
Received date: 8 April 2015; Accepted date: 10 June 
2015; Published date: 17 June 2015.
Citation: Reina S, Pisoni C, Eimon A, Carrizo C, 
Ganzinelli S, et al. (2015) Changes in Cyclooxygenase-
2’s Expression, and PGE2’s and 6-keto-PGF1α’s 
Levels in the Presence of the Muscarinic 
Acethylcholine Receptor Antibody in Primary Sjögren 
Syndrome. Int J Dent Oral Health 1 (3): doi http://dx.doi.
org/10.16966/2378-7090.115
Copyright: © 2015 Reina S et al. This is an open-
access article distributed under the terms of 
the Creative Commons Attribution License, 
which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original 
author and source are credited.
*Corresponding author: Enri Borda, M.D., Ph.D., Pharmacology Unit, School of Dentistry, University 
of Buenos Aires,Marcelo T de Alvear 2142 – 4 “B”, 1122 AAH. Ciudad Autónoma de Buenos Aires, 
Argentina, Tel: +54-11-4964-1276; E-mail: enri@farmaco.odon.uba.ar
Abstract
Aims
This paper investigates the action of M3 muscarinic acetylcholine receptor antibody present in serum from patients with Sjögren syndrome (SS). 
Methods
Enzyme-linked immunoabsorbent assay (ELISA) was performed in the presence or absence of different enzymatic and specific receptors’ 
antagonist drugs. The levels and the generation of PGE2, 6-keto-PGF1α and cyclic AMP (cAMP) in rat submandibular gland acini’s preparations 
and in serum from pSS patients were measured in the presence of pSS IgG anti M3 peptide. COX-2 mRNA gene’s expression at Real Time PCR 
was done in acini’s preparations from rat submandibular gland in the presence of the autoantibodies alone or once previously incubated with 
different inhibitors.
Results
In this study, we show that the activation of M3 mAChR of rat submandibular gland acini’s preparation triggers an increment both in the production 
of COX-2 mRNA gene’s expression and in the production of PGE2 and 6-keto-PGF1α. These phenomena are accompanied by an increment in the 
production of cAMP in the acini’s preparation and do not affect COX-1 mRNA’s levels.  Both prostanoids are augmented in the sera of pSS patients 
as compared with healthy individuals. 
Conclusions 
The present study suggests a complex interplay between different factors involved in adaptativa autoimmunity in pSS patients at the level 
of exocrine glands. The presence of pSS IgG anti M3 peptide, the enhancement of COX-2 mRNA gene’s expression and the increment in the 
generation of PGE2 and 6-keto-PGF1α abolished by M3 specific cholinergic antagonist, could provide evidence of a link between autoimmunity and 
the submandibular gland parasympathetic system in the course of Sjögren’s syndrome. This evidence is further supported by an increment in the 
production of AMP cyclic nucleotide (cAMP), and the subsequent induction of desensitization, internalization and/or intracellular degradation of the 
glandular M3 mAChR displayed by the cholinergic autoantibody. All of these statements cited above, are responsible for xerostomy, xerophthalmia 
and other parasympathetic symptoms observed in SS patients. 
Keywords: Autoantibodies; Sjögren’ syndrome; PGE2; PGI2; cAMP; COX-2 mRNA
Introduction
Primary Sjögren’s syndrome (pSS) is a common chronic autoimmune 
disease characterized by the inflammation of exocrine glands and the 
clinical signs of xerostomia and keratoconjuntivitis sicca. A combination 
of environmental, genetic and possibly hormonal factors leads to the 
dysregulation of the glandular epithelium, mononuclear cell infiltration 
and abnormal lymphocyte activation and proliferation [1,2]. Alter 
humoral autoimmune responses, B cell hyperactivity and autoantibodies 
production are the hallmarks of pSS [3-5].
We have reported the presence of autoantibodies against rat salivary 
and lacrimal glands M3 muscarinic acetylcholine receptors (mAChR M3), 
which trigger parasympathetic-receptor-mediated biological effects [6-9]. 
We also demonstrated that they are able to recognize a synthetic peptide 
corresponding in amino acid sequence to the second extracellular loop of 
the human M3 mAChR. An isolated fraction of pSS IgG rich in anti M3 
peptide antibodies could reproduce the effects of the corresponding whole 
immunoglobulin. 
These facts suggest a prominent role of the anti M3 peptide antibody in 
the mAChR-mediated effects of total pSS IgG. 
Other known facts are that the synthetic M3 peptide involved selectively 
suppresses the biological effects of SS anti M3 peptide autoantibody and the 
corresponding total IgG. The neurotransmitter mAChR autoantibodies 
coexist with the presence of other important autoantibodies to Ro/SS-A 
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Preparation of submandibular gland acini’s
Submandibular gland acini’s were prepared from adult female Wistar-
strain rats. Animals were used according to “The Guide to the Care and Use 
of Experimental Animals” (DHEW Publication, NIH 80-23). Glands were 
dissected away from fat, connective tissue and lymph nodes and immersed 
in a tissue chamber containing Krebs-Ringer-bicarbonate (KRB) solution 
gassed with 5% CO2 in oxygen and maintained at pH 7.4 and 37°C. All 
subsequent steps were performed at 4°C. Submandibular glands were 
minced and incubated in KRB supplemented with 10 mM HEPES and 
5.5 mM glucose (KRB-HEPES) and 0.5% bovine serum albumin (BSA), 
pH 7.4, containing collagenase (150 U/ml). Gland lobules were subjected 
to gentle pipetting. The preparation was then filtered through nylon mesh 
(150 µm pore size) and the acini’s were pellets with a 2 min centrifugation 
at 50 g. The pellet was then washed twice by centrifugation (50 g for 2 min) 
through a 4% BSA solution made with KRB-HEPES buffer. The dispersed 
acini’s were allowed to recover for 30 min in 5 ml fresh KRB-HEPES buffer 
containing 0.5% BSA [19].
Patients
The subjects of this study were 28 pSS anti-Ro/SSA positive patients 
and 25 healthy volunteers, all female, aged 39-54 years. They were selected 
from the metropolitan area of Buenos Aires (Table 1). The diagnosis of 
pSS fulfilled the criteria described by Vitali et al. [20] and was given by 
means of a positive biopsy with a score focus of 3.8 ± 0.07.
Purification of human IgG
The serum IgG fraction from patients with pSS and from normal 
individuals (control) was isolated using protein G affinity chromatography 
as described elsewhere [21]. Briefly, sera were loaded onto the protein G 
affinity column (Sigma-Aldrich, St Louis, MO, USA) equilibrated with 1 
M Tris-HCl (pH 8.0) and the columns were washed with 10 volumes of 
the same buffer. The IgG fraction was eluted with 100 mM glycine-HCl, 
pH 3.0, and immediately neutralized. The concentration and purification 
of IgG were determined using a radial immunodiffusion assay.
Serological studies
Anti-Ro-SSA procedure: Saline-soluble extractable nuclear antigens 
(ENA) were obtained from human spleen in phosphate buffered saline 
(PBS) for anti-Ro. Patient sera were tested undiluted and diffusion was 
carried out at room temperature in a humidified chamber for 48 hours. 
Precipitin lines were identified by comparison with reference sera. ELISAs 
for total anti-Ro (60 kD and 52 kD Ro-proteins) was performed with a 
commercial Kit based on purified antigens (Orgentec Diagnostika, Mainz, 
Germany) and the assays were carried out according to the manufacturer’s 
protocols on an automated ELISA instrument (Radim, Pomezia RM, 
Italy). Values greater than 25 UI/ml was considered positive (Table1).
Anti-M3 peptide IgG procedure: The IgG fraction from 28 patients 
with pSS and 25 healthy subjects was independently subjected to affinity 
chromatography on the synthesized peptide covalently linked to AffiGel 
15 gel (Bio-Rad, Richmond, CA, USA) as described by Reina et al. [8]. 
Briefly, the IgG fraction was loaded onto the affinity column equilibrated 
with PBS. The non-peptide fraction was first eluted with the same buffer. 
Specific anti-peptide antibodies were then eluted with 3 M KSCN and 1 
M NaCl, followed by immediate extensive dialysis against PBS. The IgG 
concentration of non-anti-peptide antibodies and specific antimuscarinic 
receptor peptide antibodies was determined by a radial immunodiffusion 
assay. Their immunological reactivity against muscarinic receptor peptides 
was evaluated by using ELISA. The concentration of the affinity-purified 
anti-M3 peptide IgG (1×10
-8 M) increased optical density (mean OD ± 
SEM, 2.4 ± 0.2). The non-anti-M3 peptide IgG fraction eluted from the 
column showed OD values (0.27 ± 0.06) similar to those of normal IgG 
from healthy individuals taken as control (0.26 ± 0.05). The normal IgG 
(Ro52, Ro60) or La/SS-B [10-12]. These autoantibodies are non-organ 
specific. Their role in the pathogenesis of SS has not been understood yet. 
This supports the view that the second extracellular loop is not only the 
main immunogenic region of the receptor but can be considered essential 
for the biological action of these autoantibodies.
In this context, it is important to notice that antinuclear antibodies 
(ANA) are frequently found together with the rheumatoid factor (RF) and 
anti centromere antibody (ACA) in patients with pSS in the early stages 
of the disease and at a younger age. These autoantibodies are not specific 
to SS, but show a local response to autoantigens derived from salivary 
glands aggressors, which produce these autoantibodies at the level of the 
local system [13]. Prostaglandins (PGs) are implicated in normal cellular 
processes as well as in pathophysiological conditions such as inflammation 
[14,15]. PGE2 and PGI2 are synthesised by cyclooxygenase (COX) 
and prostaglandin and prostacyclin E and I synthases in vivo. The two 
enzymes catalyse the reaction of transformation of arachidonic acid (AA) 
through PGH2 into PGE2 and PGI2. The two isoforms of COX (COX-
1 and COX-2) and PGE2 / PGI2 have been identified: In general, COX-
1 is constitutively expressed in almost all tissues and have haemostatic 
effects, whereas inflammatory processes lead to an increased expression 
of COX-2 [16] in response to inflammation; the increased expression of 
COX-2 provokes, in turn, an increment in the generation of PGE2 and 
PGI2; PGE2 has been shown to be part of the signalling events involved in 
M3 mAChR activation [17,18].   
Accordingly, the aim of our work is to investigate if the inflammatory 
process  provoked by the M3 mAChR IgG of  sera of pSS patients in rat 
submandibular gland and the following increased  expression of mRNA 
COX-2 and production of PGE2 and PGI2 are associated with the presence 
of M3 mAChR IgG.
Material and Methods
Ethical approval of the study protocol
The study protocol complied with the tenets of the Declaration of 
Helsinki and accomplished with the rules established by the Ethics 
Committee of the University of Buenos Aires (Buenos Aires, Argentina). 
All subjects provided written informed consent.
Drugs
A 25-mer peptide (K-R-T-V-P-D-N-Q-C-F-I-Q-F-L-S-N-P-A-V-T-
F-G-T-A-I) corresponding to the sequence of the second extracellular 
loop of the human M3 mAChR was synthesized by Peptide Genetic 
Research Company (Livermore, CA, USA)  as  previously  described  [6]. 
DuP697  5 × 10-6 M (5-bromo-2-(4-fluorophenyl)-3-(4-(methylsulfonyl) 
phenyl-thiophene); RO3144794 5 × 10-8 M (R-3-(4-fluoro-phenyl)-2-[5-
(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-propionic 
acid); PF-04418948 2 × 10-9 M (1-(4-fluorobenzoyl)-3-([6-methoxy-2-
naphthyl) oxy] [methyl] azetidine-3-carboxylic acid) were from Tocris 
Cookson (Ellisville, MO, USA).  Stock solutions were freshly prepared in 
the appropriate buffers and the drugs were diluted in water to achieve the 
final concentrations stated in the text.
Animals
Male Wistar rats weighing 250-300 g from the Pharmacologic Bioterium 
School of Dentistry, University of Buenos Aires) were used throughout. 
The animals housed in standard environmental conditions were fed with 
a commercial pellet diet and water ad libitum. For surgical removal of 
submandibular glands, the animals were killed with an overdose of 
an i.p. ketamine/xylazine mixture (100 and 16 mg/kg respectively). 
The experimental protocol followed the Guide to The Care and Use of 
Experimental Animals (DHEW Publication, NIH 80-23).
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fraction purified by affinity column chromatography gave a negative result 
(0.30 ± 0.03) (Table1). ELISA was performed as described previously [22].
Real-time PCR of COX-2
Total RNA was extracted from rat submandibular gland acini’s using 
Trizol reagent (Invitrogen Life Technologies, CA, USA) according to the 
manufacturer´s protocols as previously reported [23]. One μg of total RNA 
was treated with DNAase Kit FERMENTAS, St. Leon-Rot, Germany) and 
subsequently reverse-transcribed into cDNA using Iscrip  cDNA Synthesis 
Kit (Bio-Rad Laboratories, CA, USA) according to the manufacturer`s 
protocols. One hundred nanogram of cDNA was used for the reaction 
mixture. The amplification of COX-2 and glyceraldehydes 3-phosphate 
dehydrogenase (GAPDH) was performed using iTaqTM Fast SYBR® Green 
Supermix with ROX (Bio-Rad). The couples of primers that resulted from 
using the 7900HT Fast Real-Time PCR system (Applied Biosystems, CA, 
USA) were as follows: COX-2-: 5′GCTCAGCCATACAGCAAATCC; 
rev: 5′CCAAAATTAAC;  GAPDH: 5′TCACCAGGGCTGCTTTTAAC; 
rev: 5′GACAAGCTTCCCGTTCTCAG. COX-2 mRNA expression were 
normalized with GAPDH levels. Gene expression assays were performed 
by relative quantification with comparative cycle threshold using ABI 
Prism SDS 2.-1 software (Applied Biosystems) and the results were 
expressed as per cent of changes.
PGE2 and 6-keto-PGF1α procedure
Tissue (submandibular gland acini’s) PGE2 and 6-keto-PGF1α were 
measured by ELISA, which was carried out according to the manufacturer’s 
protocols (Biotrack Enzyme Immune Assay System, Amersham 
Bioscience, Piscataway, NJ, USA). The OD   cut-off values for pSS serum 
PGE2 were 42.6 ng/L and 6-keto-PGF1α 64.2 ng/L; the OD cut-off values 
for gland acini’s PGE2 were 0.5 ng/ml and 6-keto-PGF1α 0.62 ng/ml (basal 
control). All gland acini’s samples were frozen promptly after collection 
and kept at -80°C until used for PGE2 and 6-keto-PGF1α determination. 
The result in serum is expressed as ng/L and in submandibular gland 
acini’s in ng/ml.
Determination of cyclic AMP levels
To determine cyclic AMP (cAMP) levels tissues (submandibular gland 
acini’s) were incubated in 1 ml of Krebs Ringer Bicarbonate (KRB) for 30 
min. After incubation, submandibular gland acini’s were homogenized in 
2 ml of absolute ethanol and centrifuged at 6000 g for 15 min at 4°C. Pellets 
were then re-homogenized in ethanol–water (2:1) and supernatants were 
collected and evaporated to dryness. The residue was dissolved in 400 μl 
of 50 μM sodium acetate buffer, pH 6.2 and aliquots of 100 μl were taken 
for nucleotide determination using a radio immunoassay procedure with 
a 3H-cAMP-RIA kit from Dupont New England Nuclear (Boston, MA, 
USA).
Statistical analyses
The Student’s “t” test for unpaired values was used to determine the level 
of significance. In case multiple comparisons were necessary after analysis 
of variance the Student-Newman-Keuls test was applied. Differences 
between means were considered significant if P<0.05.
Results
Effect of pSS IgG anti M3 peptide
To determine the effect of pSS IgG anti M3 peptide on gland acini’s we 
analyzed the time-course of COX-2 mRNA expression by Real Time-PCR 
(Figures 1A and B). At the sixth hour presence of pSS IgG anti M3 (1 × 10
-8 
M), COX-2-mRNA was significantly (P<0.001) increased versus normal 
IgG anti M3, which is ineffective in this studied system (control). When 
the autoantibody was incubated in the presence of DuP697 (1 × 10-6 M) 
[a specific COX-2 antagonist] under the same experimental conditions, 
it abrogated the increment of COX-mRNA’s expression in a significant 
manner (P<0.01). However, when the experimental protocol was assessed 
in the presence of M3 mAChR specific antagonist J104127 (1 × 10
-8 M) 
and/or synthetic M3 peptide (5 × 10
-6 M) the change in COX-2 mRNA 
expression by the pSS IgG anti M3 did not reach statistical significance 
(Figure 1C). COX-1 mRNA expression did not change significantly in our 
preparation system.
Effect of pSS IgG anti M3 on the production of PGE2 and 6-keto-
PGF1α
As shown in Figure 2, the dose-response concentration curve of PGE2 (A) 
and 6-keto-PGF1α (C) in the presence of pSS IgG anti M3 on submandibular 
gland acini’s increased the production of both prostanoid, reaching the 
maximal action when the antibody is at a concentration of  1 × 10-8 M. 
The increment in the generation of both prostanoids is abrogated, reaching 
values similar to basal ones, when the tissue preparations are incubated with 
prostanoid antagonists PF-04418948 2 × 10-9 M (Figure 2A) and RO3244794 
5 × 10-8 M (Figure 2C) for PGE2 and 6-keto-PGF1α respectively, and in the 
presence of synthetic M3 peptide 5 × 10
-6 M (Figures 2A and 2C). Normal 
(n) IgG anti M3 peptide was ineffective in our study system (Figure 2 
histogram B and D).
Effect of pSS IgG anti M3 on the production of cyclic AMP
Synthetic M3 peptide 5 × 10
-6 M, PGE2 5 × 10-6 M and 6-keto-PGF1α 5 × 
10-6 M were accompanied by modification of cAMP production associated 
positively with the increased amount of both prostanoids (Figure 3 and 








Current age, mean years ± SD 48.5 ± 10.8 38.5 ± 10.1
Disease duration, mean years 
± SD 4.3 ± 2.4 N/A
Female gender, n (%) 28 (100) 30 (100)
Organ/system involved
Xerostomia, n (%)  28 (100) N/A
Xerophthalmia, n (%)   28 (100) N/A
Xerodermia, n (%)   28 (100) N/A
Fatigue, n (%)    24 (85.7) N/A
Current antibodies
Anti-Ro/SSA positive, n (%) 22 (78) N/A
Anti-La/SSB positive, n (%) 22 (78) N/A
Anti-M3 synthetic peptide IgG, 
n (%)  28 (100)   2 (6.6)
Table 1: Demographic and clinical characteristics of primary Sjögren 
syndrome patients and healthy individuals
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In Figure 3A it can be seen that the production of cAMP reaches 
maximal increment at 1 × 10-8 M pSS IgG anti M3 peptide. This stimulatory 
effect was almost abolished by pre-treating submandibular gland acini’s 
with J104127 1 × 10-8 M and/or synthetic M3 peptide 5 × 10
-6 M. The 
normal IgG anti M3 peptide gave negative results (Figure 3A).
To ascertain if this cAMP increment is responsible for the augmented 
generation of PGE2 and 6-keto-PGF1α in our preparation, we study the 
action of both prostanoids on the production of this nucleotide. Figure 3B 
and Figure 3C shows that both prostaglandins are able to increase cAMP 
production, whereas the selective prostanoids antagonists   (PF-04418948 
for PGE2 and RO3244794 for 6-keto-PGF1α) blunt the stimulatory action 
provoked by the prostaglandins.
Determination of the levels of PGE2 and 6-keto-PGF1α in 
serum in pSS patients in comparison with healthy individuals 
(controls)
The distribution of PGE2 and 6-keto-PGF1α was studied in serum of pSS 
patients and in healthy individuals.  The scatter grams of Figure 4 show 
both 6-keto-PGF1α’s (A) and PGE2’s (B) concentration in serum from pSS 
patients and healthy individuals (control). The concentration of 6-keto-
PGF1α and PGE2 in serum of pSS patients was two standard deviations 
higher than that in normal individuals (P<0.001).
Discussion 
In this study, we show that the activation of M3 mAChR of rat 
submandibular gland acini’s preparation triggers an increment in 
the production of COX-2 mRNA gene’s expression together with an 
increment in the production of PGE2 and 6-keto-PGF1α. These phenomena 
are accompanied by an increment in the production of cAMP in acini’s 
preparation without affecting COX-1 mRNA levels.   
Positive regulation by cholinergic agonists has been described in 
different tissues [24-27] including rat submandibular gland [28]. We 
observed that such stimulation was due to COX-2’s activation through M3 
mAChR glandular acini’s activation: this increment was prevented by the 
specific blockade of this enzyme [29], by the cholinoceptor antagonist agent 
[30] and by M3 synthetic peptide [16]. However, the rat submandibular 
gland constitutively expressed COX-1 [31]. In most cells, COX-1 mediates 
 
Figure 2: A: Concentration-response curve of pSS IgG anti M3 peptide 
alone (●) or in the presence of PF-04418948 2x10-9 M  (■) and J104127 
1x10-8 M  (▲) on the generation of PGE2; B: Histogram shows in comparative 
form in acini’s preparations alone, the action of the maximal concentration 
(1x10-8 M) of pSS IgG anti M3 peptide in comparison to normal (n) IgG anti 
M3 peptide on the generation of PGE2; C:  Concentration-response curve 
of pSS IgG anti M3 peptide alone (●) or in the presence of RO3244794 
5x10-8 M  (■) and J104127 1x10-8 M  (▲) on the generation of 6-keto-
PGF1α; D: Histogram shows in comparative form in acini’s preparations 
alone, the action of the maximal concentration (1x10-8 M) of pSS IgG anti 
M3 peptide in ○Values are mean ± SEM of 5 experiments in each group 
performed by duplicate; *P<0.001 versus values in dashed line; **P<0.0001 
versus basal (b) and nIgG anti M3 values.
 
Figure 1: Bar graph depicts the mRNA expression of cyclooxygenase-2 (COX-2) 
in rat submandibular gland acini’s. The acini’s from eight rats were treated during 
3 hours with or without (basal) pSSIgG (1x10-7 M) or IgG anti M3 peptide (1x10
-8 
M) or n IgG anti M3 peptide from healthy individuals (normal: n IgG) and primary 
Sjögren`s syndrome patients (pSS patients) respectively. In inhibitory experiments, 
COX-2 inhibitor (DuP697 5x10-6 M), M3 specific mAChR antagonist (J104127 
1x10-9 M) and M3 synthetic peptide (1x10-5 M) were added to acini’s 30 minutes 
before pSS IgG or pSS IgG anti M3 treatment. The COX-2 mRNA was extracted 
using quantitative real-time polymerase chain reaction and the levels of COX-2 
were measured. Values are mean ± SEM expressed as per cent of change of 
5 experiments in each group performed by duplicate. *P<0.0001 versus basal 
(acini’s alone); ** P<0.001 versus pSS IgG or pSS IgG anti M3.
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physiological responses such as the modulation of the autonomic nervous 
system, whereas, COX-2 mainly plays a role in inflammation, infection 
and cellular proliferation [22]. In our case, the autoantibody from sera 
of pSS patients was able to stimulate the COX-2 mRNA’s expression. This 
was the case due to the fact that when this pSS IgG anti M3 peptide binds 
to, and activates, the M3 mAChR receptor present in the membrane of 
gland acinar cells; it provokes an inflammatory process, in which COX-
2 is expressed [23]. COX-1’s expression did not change significantly in 
the rat submandibular gland acini’s preparations in the presence of the 
cholinergic autoantibody.
On the other hand, pSS IgG anti M3 peptide has a capacity to stimulate 
the production of PGE2 and 6-keto-PGF1α in concentration-response curve 
fashion in gland acini’s preparations. However, the stimulatory action of 
these autoantibodies is inhibited by M3 mAChR’s specific antagonist [30], 
by PGE2’s specific antagonist [31], 6-keto-PGF1α‘s antagonist [32] and M3 
synthetic peptide [16]. This shows that the action of these autoantibodies 
on acini’s glandular preparations act as an inducer of the augmented 
generation of both prostanoids. The prostanoids, in turn, are able to 
maintain chronic inflammatory processes at the level of submandibular 
gland in the chronic course of pSS.  
It has long been known that prostanoids can be generated by most 
cells in response to mechanical, thermal or chemical injuries, and/or 
inflammatory process [33]. Accordingly, the proinflammatory effects 
of PGE2 and PGI2 have been studied widely in numerous models of 
inflammation [34]; PGE2 and PGI2’s action, are also seen as being 
able to contribute to the vasodilatory blood flow in all tissues acting as 
proinflammatory cytokine [35]. Both prostanoids can be considered to 
play a crucial role in the process of inflammation (occurring at the level of 
the exocrine glands, i.e., eye and salivary gland), which is itself responsible 
for the xerophthalmia and xerostomia present in pSS provoked by the 
cholinergic autoantibody.    
In all these pharmacological approaches the increment of COX-2 / 
PGE2 / PGI2 in the submandibular gland acini’s preparations through 
the action of pSS IgG anti M3 peptide is shown to be the result of the 
ability of this cholinergic autoantibody present in the sera of pSS patients 
to mobilize arachidonic acid from phospholipids. The presence of this 
autoantibody is shown to lead to the subsequent activation and increase of 
the COX-2 mRNA’s expression accompanied by a large amount of PGE2/
PGI2. Both prostanoid are thus shown to be responsible of the installation 
of the neuroinflammatory pathophysiological processes at the level of 
glandular salivary gland.
The increment in PGE2 and 6-keto-PGF1α is mediated by cAMP’s 
increased production, whereas the increased production of this nucleotide 
 
Figure 3: A: Concentration-response curve of pSS IgG anti M3 peptide 
alone (●) and in the presence of J104127 1x10-8 M (▲) and M3 synthetic 
peptide 1x10-5 M (▼) normal IgG (black square) submandibular gland 
acini’s preparation cAMP production.  B and C: As control, concentration-
response curve of PGE2 alone (∆) and PF-04418948 2x10
-9 M plus PGE2 
(∆) and 6-keto-PGF1α alone (○) and RO3244794 5x10
-8 M plus 6-keto-
PGF1α (□) on submandibular gland acini’s preparation cAMP production. 
Different points represent the media ± SEM of 4 experiments performed 
by duplicate in each concentration. *P<0.0001 versus different inhibitors 
(dotted/dashed lines in A, B and C).
Additions cAMP(pmol/mg tissue wet weight) N
pSS IgG anti M3
(1x10-8 M) 7.04 ± 0.2 * 6
+ M3 synthetic peptide
(1x10-5 M) 1.26 ± 0.1 ** 5
+ RO3244794
(5x10-8 M) 7.20 ± 0.3 5
+ PF-04418948
(2 x10-9 M) 7.15 ± 0.2 5
PGE2
(1x10-9 M) 4.42 ± 0.2 5 
+ PF-04418948
(2 x10-9 M) 1.81 ± 0.2 5
6-keto-PGF1α
(1x10-9 M) 6.11 ± 0.1 6
+ RO3244794
(5x10-8 M) 1.91 ± 0.2 5
normal IgG anti M3
(1x10-8 M) 2.01 ± 0.1 6
Table 2: Tissue production of cAMP in rat submandibular gland acini in the 
presence of pSS IgG anti M3, PGE2 and 6-keto-PGF1α
Values are mean ± SEM of n experiments performed by duplicate. * 
P<0.0001 versus normal IgG anti M3; ** P<0.0001 versus pSS IgG anti 
M3, PGE2 and 6-keto-PGF1α. PF-04418948 (PGE2 antagonist) and 
RO3244794 (PGI2 antagonist) did not have any effect per se in the system.
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is inhibited by the prostanoids’ specific antagonists. In acini’s preparations 
pSS IgG anti M3 peptide is able per se to enhance cAMP’s production and 
this nucleotide is blunted by M3 cholinergic antagonist and M3 synthetic 
peptide. IgG anti M3 of normal individuals (control) is without effect in 
our system. When pSS IgG anti M3 peptide from sera of pSS patients 
bind to, and activate, rat submandibular gland acini’s M3 mAChR, the 
autoantibody leads to the activation of adenylate cyclase. What follows 
is an increased production of cAMP together with the increment of the 
inflammatory mechanism of the gland. This can be explained by the 
fact that the nucleotide ultimately makes the same contribution to the 
modulation of the gland apoptotic pathways as observed in SS [36].                        
Conclusion
The present study suggests a complex interplay between different 
factors involved in adaptativa autoimmunity in pSS patients at the level 
of exocrine glands. 
The presence of pSS IgG anti M3 peptide, the enhancement of COX-
2 mRNA gene’s expression and the increment in the generation of PGE2 
and 6-keto-PGF1α - abolished by M3 specific cholinergic antagonist - 
could provide a link between autoimmunity and the submandibular 
gland parasympathetic system in the course of Sjögren syndrome. This 
view is further supported by the increment in the production of AMP 
cyclic nucleotide (cAMP). Another important fact in this concern 
is that the cholinergic agonist activity displayed by the cholinergic 
autoantibody could subsequently induce desensitization, internalization 
and/or intracellular degradation of the glandular M3 mAChR, resulting 
in xerostomy, xerophthalmia and other parasympathetic symptoms 
observed in SS patients. 
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